Aminoguanidine inhibits IL‑1β‑induced protein expression of iNOS and COX‑2 by blocking the NF‑κB signaling pathway in rat articular chondrocytes

Abstract

Osteoarthritis is a chronic joint disease which has a serious impact on the health and quality of life of affected humans and animals. As an inhibitor of inducible nitric oxide synthase (iNOS), aminoguanidine (AG) displays anti-inflammatory effects. The purpose of the present study was to investigate the effect of AG on the expression of iNOS and cyclooxygenase-2 (COX-2), and the activity of the NF-κB signaling pathway in rat chondrocytes stimulated by interleukin-1β (IL-1β). The viability of chondrocytes treated with AG (0.3, 1 or 3 mM) alone was determined using a Cell Counting Kit-8 assay. Subsequently, the chondrocytes were treated with either 10 ng/ml IL-1β alone, or co-treated with increasing concentrations of AG (0.3, 1 or 3 mM) and 10 ng/ml IL-1β. The protein levels of COX-2, iNOS, phosphorylated (p)-p65, p65, p-NF-κβ inhibitor α (IκBα), IκBα, p-inhibitor of NF-κβ-β (IKKβ) and IKKβ were evaluated by western blotting. NF-κB translocation was determined by immunofluorescence analysis. Western blotting and reverse transcription-quantitative PCR were used to detect expression levels of relevant proteins/genes. The results suggested that the inhibitory effect of AG on the protein and gene expression levels of iNOS and COX-2 in IL-1β-treated chondrocytes was dose-dependent. In addition, AG decreased the level of phosphorylation of IKKβ, IκBα and NF-κB p65, the degradation of IKKβ, IκBα and p65, and the translocation of NF-κB in IL-1β-stimulated chondrocytes. The most significant inhibitory effect of AG was observed at a concentration of 1 mM. Therefore, the present study suggested that AG may serve as a potential agent to reduce the inflammatory response of chondrocytes stimulated by IL-1β.